Trials / Completed
CompletedNCT05827874
A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the effect of nipocalimab treatment on the antibody (a protein made in the body to response to a foreign substance) response following tetanus, diphtheria, pertussis (Tdap) vaccination in healthy participants at Week 4.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nipocalimab | Nipocalimab will be administered as an IV infusion. |
| BIOLOGICAL | Tdap | Tdap will be administered as an IM injection. |
| BIOLOGICAL | PPSV23 | PPSV23 will be administered as an IM injection. |
Timeline
- Start date
- 2023-04-12
- Primary completion
- 2023-10-04
- Completion
- 2023-10-04
- First posted
- 2023-04-25
- Last updated
- 2025-03-04
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05827874. Inclusion in this directory is not an endorsement.